Physicians' Academy for Cardiovascular Education
Click here to watch this as part of CME accredited course

Hypoglycemia in cardiovascular medicine: why worry?

5 Things a cardiologist needs to know about diabetes

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

5 Things a cardiologist needs to know about diabetes Several factors make a diabetes patient more vulnerable to severe hypoglycemia events, which are associated with higher CV morbidity and mortality. Prof Schernthaner discusses how hypoglycemia can be prevented.

Click here to watch this as part of CME accredited course

Video navigation menu

  • How common is severe hypoglycemia and which patients are at risk? 0:39
  • Associations between hypoglycemia and CV morbidity and mortality 3:48
  • The DEVOTE trial: CV death risk soon after an SH event 9:47
  • Pathophysiological CV consequences of hypoglycemia 11:17
  • Severe hypoglycemia should be avoided in risk situations in T2DM: how to achieve this 12:40

Educational information

This educational video is part of a series called '5 Things a cardiologist needs to know about diabetes' that are aimed to guide cardiologists in management of patients with type 2 diabetes, since the cardiology practice is increasingly confronted with these patients. This series covers five topics that help cardiologists understand what is important when treating patients with diabetes, and what risks these patients face.

This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.

Faculty

Prof. Guntram Schernthaner is Head of the Department of Medicine at Rudolfstiftung Hospital-Vienna, Austria. His research interests include diabetes mellitus (Insulin Therapy, Oral Hypoglycemic Agents, Immunpathology, Immunogenetics and Immunotherapy of type-I Diabetes, Insulin Resistance, Cardiovascular Disease; Haemostasis, Cardiovascular Disease, Diabetic Nephropathy, Diabetic Retinopathy, Peripheral Vascular Disease, Gestational Diabetes).

Disclosures

This educational series is funded by an unrestricted educational grant provided by Merck & Pfizer.

Also see: Key Classes of antidiabetic drugs: How do they work?

Share this page with your colleagues and friends: